Frequency of IL-10+CD19+ B Cells in Patients with Prostate Cancer Compared to Patients with Benign Prostatic Hyperplasia

Background: The function of the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common cancer in men. Regulatory B cells (Bregs) are a new subtype of B cells that have suppressive roles in the immune system. Inter- leukin-10 (IL-10) is a dominant mediator of immune suppression released by Bregs.

Objective: The purpose of this research was to examine the frequency of CD19+IL10+ B cells and IL-10 mRNA expression in patients with PC compared to patients with benign prostatic hyperplasia (BPH).

Methods: Forty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were en- tered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR).

Results: The frequency of CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than patients with BPH. Also, there was no meaningful relationship between the frequency of IL-10+CD19+ B cells and gleason scores in patients with PC.

Conclusions: Our findings suggested that frequency of IL-10+CD19+ B cells correlates with progressive stage of PC.